MX386024B - Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas. - Google Patents
Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas.Info
- Publication number
- MX386024B MX386024B MX2020001835A MX2020001835A MX386024B MX 386024 B MX386024 B MX 386024B MX 2020001835 A MX2020001835 A MX 2020001835A MX 2020001835 A MX2020001835 A MX 2020001835A MX 386024 B MX386024 B MX 386024B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- patient
- conditions
- vehicle
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 7
- 201000010099 disease Diseases 0.000 title abstract 5
- 206010012689 Diabetic retinopathy Diseases 0.000 title 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 abstract 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261643058P | 2012-05-04 | 2012-05-04 | |
| US201261643051P | 2012-05-04 | 2012-05-04 | |
| US201261643178P | 2012-05-04 | 2012-05-04 | |
| US201361781907P | 2013-03-14 | 2013-03-14 | |
| PCT/US2013/039562 WO2013166449A2 (en) | 2012-05-04 | 2013-05-03 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020001835A MX2020001835A (es) | 2021-09-09 |
| MX386024B true MX386024B (es) | 2025-03-18 |
Family
ID=49515046
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001835A MX386024B (es) | 2012-05-04 | 2013-05-03 | Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas. |
| MX2014013341A MX2014013341A (es) | 2012-05-04 | 2013-05-03 | Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013341A MX2014013341A (es) | 2012-05-04 | 2013-05-03 | Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9957224B2 (enExample) |
| EP (2) | EP3741742A1 (enExample) |
| JP (6) | JP2015518491A (enExample) |
| KR (1) | KR20150013240A (enExample) |
| CN (3) | CN116850163A (enExample) |
| AU (1) | AU2013256029A1 (enExample) |
| BR (1) | BR112014027571B1 (enExample) |
| CA (1) | CA2872433C (enExample) |
| EA (1) | EA201492031A1 (enExample) |
| ES (1) | ES2792923T3 (enExample) |
| HK (2) | HK1203478A1 (enExample) |
| IL (1) | IL235446A0 (enExample) |
| MX (2) | MX386024B (enExample) |
| PH (1) | PH12014502449A1 (enExample) |
| SG (1) | SG11201407162SA (enExample) |
| TW (1) | TW201406707A (enExample) |
| WO (1) | WO2013166449A2 (enExample) |
| ZA (1) | ZA201408592B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010003667A (es) | 2007-10-05 | 2010-09-28 | Acucela Inc | Compuestos alcoxi para el tratamiento de enfermedades. |
| ES2897527T3 (es) * | 2009-07-02 | 2022-03-01 | Acucela Inc | Farmacología de moduladores del ciclo visual |
| WO2013023059A2 (en) | 2011-08-10 | 2013-02-14 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of autoimmune and inflammatory diseases |
| EP2804605A4 (en) | 2012-01-20 | 2015-07-08 | Acucela Inc | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES |
| TW201406707A (zh) | 2012-05-04 | 2014-02-16 | Acucela Inc | 用以治療糖尿病性視網膜病變及其他眼部疾病之方法 |
| AU2014248878A1 (en) * | 2013-03-12 | 2015-09-24 | Acucela Inc. | Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders |
| JP6532854B2 (ja) * | 2013-03-14 | 2019-06-19 | オプティメディカ・コーポレイションＯｐｔｉｍｅｄｉｃａ Ｃｏｒｐｏｒａｔｉｏｎ | レーザ水晶体嚢硝子体切開術 |
| AU2015243261B2 (en) | 2014-04-10 | 2020-06-25 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of ocular diseases and disorders |
| US10792374B2 (en) | 2015-10-09 | 2020-10-06 | Case Western Reserve University | Compositions and methods for the delivery of nucleic acids |
| CA3054735A1 (en) | 2017-02-27 | 2018-08-30 | Case Western Reserve University | Visual cycle modulators |
| US11712160B2 (en) * | 2017-12-28 | 2023-08-01 | Nikon Corporation | Image processing method, image processing program, image processing device, image display device, and image display method |
| MX2018008165A (es) * | 2018-06-29 | 2019-12-30 | Centro De Retina Medica Y Quirurgica S C | Sistema portátil para la identificación de casos potenciales de edema macular diabético mediante procesamiento de imagen e inteligencia artificial. |
| EP3817808A4 (en) | 2018-07-07 | 2022-04-06 | Acucela Inc. | DEVICE FOR PREVENTING RETINAL HYPOXIA |
| US11402662B2 (en) | 2018-07-30 | 2022-08-02 | Acucela Inc. | Optical designs of electronic contact lens to decrease myopia progression |
| WO2020078865A1 (en) * | 2018-10-16 | 2020-04-23 | F. Hoffmann-La Roche Ag | Use of akt inhibitors in ophthalmology |
| ES2970996T3 (es) * | 2018-10-19 | 2024-06-03 | Medicinova Inc | Tratamiento de la lesión macular asociada a la esclerosis múltiple con ibudilast |
| JPWO2020240867A1 (enExample) * | 2019-05-31 | 2020-12-03 | ||
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| EP4003250A4 (en) | 2019-07-31 | 2023-08-23 | Acucela Inc. | DEVICE FOR PROJECTING IMAGES ON THE RETINA |
| CN114730098A (zh) | 2019-09-16 | 2022-07-08 | 奥克塞拉有限公司 | 用于被设计来抑制近视发展的电子软隐形眼镜片的组装工艺 |
| TW202203521A (zh) | 2020-02-21 | 2022-01-16 | 美商艾尤席拉有限公司 | 電子隱形眼鏡之充電盒 |
| CN111617313B (zh) * | 2020-04-29 | 2022-09-06 | 天津医科大学眼科医院 | 一种眼用线性凝胶在作为临床孔源性视网膜脱离药物方面中的应用 |
| JP2023526048A (ja) | 2020-05-13 | 2023-06-20 | アキュセラ インコーポレイテッド | 近視治療のための電気切替可能眼鏡 |
| CN115769128A (zh) | 2020-06-08 | 2023-03-07 | 奥克塞拉有限公司 | 使用周边散焦治疗进展型屈光不正的贴戴式器件 |
| JP2023529875A (ja) | 2020-06-08 | 2023-07-12 | アキュセラ インコーポレイテッド | 非点収差を治療するための非対称投影を伴うレンズ |
| JP2023528301A (ja) | 2020-06-08 | 2023-07-04 | アキュセラ インコーポレイテッド | 屈折異常を治療するための周辺網膜上への脱焦点化された画像の投影 |
| US11281022B2 (en) * | 2020-06-10 | 2022-03-22 | Acucela Inc. | Apparatus and methods for the treatment of refractive error using active stimulation |
| US11209672B1 (en) | 2021-04-06 | 2021-12-28 | Acucela Inc. | Supporting pillars for encapsulating a flexible PCB within a soft hydrogel contact lens |
| US11366341B1 (en) | 2021-05-04 | 2022-06-21 | Acucela Inc. | Electronic case for electronic spectacles |
| US20240269111A1 (en) * | 2021-05-16 | 2024-08-15 | Metanoia Bio Inc. | Methods and compositions for treating ocular neovascular disease |
| JP7829241B2 (ja) * | 2021-06-03 | 2026-03-13 | 国立大学法人大阪大学 | 未熟児網膜症スクリーニング方法、スクリーニング装置及び学習済モデル |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| US20240408056A1 (en) * | 2023-06-12 | 2024-12-12 | Synaptogenix, Inc. | Methods for repairing nerve damage using pkc activating therapeutic agents |
| WO2026076289A1 (en) * | 2024-10-03 | 2026-04-09 | Mingsight Pharmaceuticals, Inc. | Treatment of diabetic eye disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| US20030181531A1 (en) * | 2003-02-11 | 2003-09-25 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| HRP20040406A2 (en) * | 2001-11-09 | 2005-02-28 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
| CN1964706A (zh) * | 2004-03-17 | 2007-05-16 | 拉斯·M·拉森 | 通过抑制视觉周期预防视网膜病 |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| MX2009011360A (es) * | 2007-04-20 | 2010-02-12 | Acucela Inc | Compuestos derivados de estirenilo para tratar enfermedades y trastornos oftalmicos. |
| NZ601866A (en) | 2007-06-29 | 2013-12-20 | Acucela Inc | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders |
| MX2010003667A (es) * | 2007-10-05 | 2010-09-28 | Acucela Inc | Compuestos alcoxi para el tratamiento de enfermedades. |
| AR070950A1 (es) | 2007-11-01 | 2010-05-19 | Acucela Inc | Compuestos derivados de amina, composiciones farmaceuticas de ellos, compuestos inhibidores de produccion de 11-cis-retinol y metodos para tratar enfermedades y trastornos oftalmicos |
| KR101395952B1 (ko) | 2008-09-05 | 2014-05-21 | 어큐셀라 인코포레이티드 | 안과 질환 및 장애 치료를 위한 황-연결 화합물 |
| BRPI0919920A2 (pt) * | 2008-10-22 | 2016-02-16 | Acucela Inc | compostos para tratamento de doenças e desordens oftálmicas |
| ES2897527T3 (es) * | 2009-07-02 | 2022-03-01 | Acucela Inc | Farmacología de moduladores del ciclo visual |
| TW201406707A (zh) | 2012-05-04 | 2014-02-16 | Acucela Inc | 用以治療糖尿病性視網膜病變及其他眼部疾病之方法 |
-
2013
- 2013-04-30 TW TW102115446A patent/TW201406707A/zh unknown
- 2013-05-03 WO PCT/US2013/039562 patent/WO2013166449A2/en not_active Ceased
- 2013-05-03 US US13/887,243 patent/US9957224B2/en active Active
- 2013-05-03 SG SG11201407162SA patent/SG11201407162SA/en unknown
- 2013-05-03 EA EA201492031A patent/EA201492031A1/ru unknown
- 2013-05-03 CN CN202310810454.4A patent/CN116850163A/zh active Pending
- 2013-05-03 KR KR1020147034091A patent/KR20150013240A/ko not_active Withdrawn
- 2013-05-03 CN CN201380035735.1A patent/CN104411678A/zh active Pending
- 2013-05-03 EP EP20169968.3A patent/EP3741742A1/en active Pending
- 2013-05-03 CA CA2872433A patent/CA2872433C/en active Active
- 2013-05-03 BR BR112014027571-8A patent/BR112014027571B1/pt active IP Right Grant
- 2013-05-03 AU AU2013256029A patent/AU2013256029A1/en not_active Abandoned
- 2013-05-03 EP EP13784718.2A patent/EP2844636B1/en active Active
- 2013-05-03 MX MX2020001835A patent/MX386024B/es unknown
- 2013-05-03 ES ES13784718T patent/ES2792923T3/es active Active
- 2013-05-03 MX MX2014013341A patent/MX2014013341A/es active IP Right Grant
- 2013-05-03 JP JP2015510493A patent/JP2015518491A/ja active Pending
- 2013-05-03 CN CN201710706410.1A patent/CN107865830A/zh active Pending
- 2013-05-03 HK HK15103833.8A patent/HK1203478A1/xx unknown
-
2014
- 2014-11-02 IL IL235446A patent/IL235446A0/en unknown
- 2014-11-03 PH PH12014502449A patent/PH12014502449A1/en unknown
- 2014-11-21 ZA ZA2014/08592A patent/ZA201408592B/en unknown
-
2015
- 2015-04-21 HK HK18106035.4A patent/HK1246646A1/zh unknown
-
2017
- 2017-11-07 JP JP2017214372A patent/JP2018024702A/ja active Pending
-
2018
- 2018-04-30 US US15/967,080 patent/US10730825B2/en active Active
-
2019
- 2019-10-11 JP JP2019187273A patent/JP2020023535A/ja active Pending
-
2020
- 2020-07-21 US US16/934,715 patent/US11795136B2/en active Active
-
2021
- 2021-02-18 JP JP2021024721A patent/JP2021075576A/ja active Pending
-
2023
- 2023-02-28 JP JP2023029073A patent/JP2023059991A/ja active Pending
- 2023-10-11 US US18/379,142 patent/US20240308951A1/en active Pending
-
2025
- 2025-02-04 JP JP2025017056A patent/JP2025069362A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502449A1 (en) | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | |
| JO3357B1 (ar) | مركبات إيميدازوبيروليدينون | |
| PH12016500582A1 (en) | Heterocyclic compounds and uses thereof | |
| BR112015028605A2 (pt) | método para prevenir, inibir ou tratar um ou mais sintomas associados com uma doença do sistema nervoso central | |
| MX356754B (es) | Formas cristalinas de un modulador del receptor androgenico. | |
| MX2015014438A (es) | Metodos de uso de interleucina-10 para tratar enfermedades y trastornos. | |
| BR112014006587A8 (pt) | Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes | |
| BR112016023039A2 (pt) | agonistas duplos dos receptores de glp-1 / glucagon derivados de exendina-4 | |
| UA117098C2 (uk) | Сполука, що містить модифікований олігонуклеотид | |
| BR112015023267A8 (pt) | composto, e medicamento para tratar um indivíduo com doença ou condição lisofosfatídica dependente de ácido | |
| UY35233A (es) | Derivados de Exendina-4 como agonistas dobles de GLP1/GIP o triples de GLP1/GIP/Glucagón | |
| EA201590583A1 (ru) | Способ получения терапевтических наночастиц | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
| EA201690881A1 (ru) | Соединения-ингибиторы аутотаксина | |
| EA201590849A1 (ru) | Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови | |
| AU2012284088A8 (en) | Heterocyclic compounds and uses thereof | |
| EA201590883A1 (ru) | Лечение помалидомидом рака у субъекта с почечной недостаточностью | |
| EA201591196A1 (ru) | Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств | |
| MD20150120A2 (ro) | Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei | |
| MX2015012444A (es) | Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos. | |
| HK1226308A1 (zh) | 使用白细胞介素-10治疗疾病和病症的方法 | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| BR112015001619A2 (pt) | manosídeos multiméricos, um processo para a preparação dos mesmos e as suas utilizações como um medicamento | |
| MX376183B (es) | Composiciones para el tratamiento de rosacea. |